Diagnostic Technologies

Numen Sensorics’ core innovation is a cellulase-linked electrochemical aptamer-sorbent assay platform (e-ELASA / e-LFT) that enables:

• Sub-femtomolar      sensitivity in real world samples
• 5-minute point-of-care testing
• High      analytical accuracy in real human serum
• Robust      performance without complex laboratory infrastructure

This technology has been validated across multiple cancer biomarkers and clinical cohorts, demonstrating strong translational and commercial potential. 

Numen Sensorics represents:

• A platform      biotechnology company, not a single-product venture
• Clinically validated,      peer-reviewed innovations
• Strong IP-generating technological      foundation
• High      scalability with low manufacturing costs
• Clear path toward regulatory      translation

By transforming liquid biopsy into rapid, affordable, and ultra-sensitive electrochemical diagnostics, Numen Sensorics is redefining cancer detection and treatment monitoring. 

Numen Sensorics aims to:

• Commercialize rapid electrochemical      cancer diagnostics
• Develop      companion diagnostics for targeted therapies
• Expand      biomarker panels across major oncology indications
• Deploy      affordable POC testing globally, including resource-limited settings
• Partner      with pharmaceutical and diagnostic companies for integrated solutions

Numen Sensorics has established a liquid-biopsy assay for serum urokinase plasminogen activator (uPA) that enables precise identification of HER2-positive and HER2-borderline cancers 

In a clinical cohort of 100 cancer patients and 30 healthy controls, serum uPA levels:

• Identified      HER2-positive tumors with 96.6% accuracy
• Achieved      an ROC AUC of 0.996
• Provided      a clinically actionable cut-off value (0.976 ng/mL)
• Differentiated      HER2-negative, borderline (2+), and overexpressed (3+) phenotypes

This assay supports:

• Non-invasive HER2 status      determination
• Resolution of borderline HER2      cases
• Improved      selection of patients for HER2-targeted therapies
• Potential      reduction in repeated invasive biopsies

Numen Sensorics has developed a breakthrough liquid-biopsy diagnostic tools based on PSA glycosylation profiling (“Glycan Score”) that enables accurate detection and stratification of primary and metastatic prostate cancer. Unlike conventional PSA concentration testing, which suffers from high false-positive and false-negative rates, the Glycan Score demonstrated 100% accurate classification of prostate cancer status in a clinical cohort study 

This innovation provides:

• Highly      specific and 100% accurate prostate cancer detection
• Clear      differentiation between localized and metastatic disease
• Improved      patient stratification for treatment decisions

A scalable alternative to current PSA-based screening limitations 

In breast cancer, particularly HER2-associated subtypes, Numen Sensorics’ serum uPA assay demonstrates strong correlation with tumor HER2 expression levels 

Specifically:

• HER2-positive      breast cancer patients and patients with a borderline expression of HER2 showed      significantly elevated serum uPA levels
• Clear      stratification between HER2-negative and HER2-overexpressed and borderline      expressed tumors
• High      diagnostic performance (AUC up to 0.988 for breast cancer cases)

This enables:

• Accurate      identification of aggressive HER2-driven breast cancers
• Improved therapy selection and      monitoring

Non-invasive follow-up during targeted treatment